Le notizie dalla Borsa Italiana del mustang-bio-announces-favorable-efficacy-and-safety-data-from-complete-waldenstrom-macroglobulinemia-cohort-of-phase-1-2-clinical-trial-of-mb-106-cd20-targeted-autologous-car-t-therapy-2247971


Condividi